NMI 300Alternative Names: NMI-300
Latest Information Update: 24 Feb 2016
At a glance
- Originator Nemucore Medical Innovations
- Class Antineoplastics; Gadolinium-containing contrast agents; Platinum complexes; Small molecules; Sphingolipids
- Mechanism of Action Diagnostic imaging enhancers; DNA cross linking agents; DNA synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Ovarian cancer